20 January 2022 (Thursday) - Stem Cell Evidence Alert

Well… I’m sitting at home on sick leave after having had a large lump cut out of my sinuses and I’m not feeling on top for, That’s the reason that I’m giving for why none of this seems to make much sense to me…

 

SELECTED ARTICLES

Comparison of Outcomes After Second Allogeneic Hematopoietic Cell Transplantation Versus Donor Lymphocyte Infusion in Allogeneic Hematopoietic Cell Transplant Patients.
Al-Shaibani, E., et al. (2021) Clinical Lymphoma, Myeloma and Leukemia [record in progress]

Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.
Bishop, M. R., et al. (2021) The New England Journal of Medicine [record in progress]

Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma.
Costa, L. J., et al (2021) Journal of Clinical Oncology: Jco2101935

Impact of donor-derived CD34+ infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT.
Czerw, T., et al. (2021) Bone Marrow Transplantation [record in progress]

Safety and efficacy of prophylactic levofloxacin in pediatric and adult hematopoietic stem cell transplant patients.
Gardner, J. C., et al. (2021) Transplantation and Cellular Therapy [record in progress]

A decision analysis for unrelated bone marrow transplantation or immediate cord blood transplantation for patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission: Unrelated BMT or immediate CBT for Ph-negative ALL.
Kako, S., et al. (2021) Transplantation and Cellular Therapy [record in progress]

Graft-Versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide versus Cyclosporine A and Methotrexate in Matched Sibling Donor Transplantation.
Nagler, A., et al. (2021) Transplantation and Cellular Therapy [record in progress]

ATG and Post-transplant Cyclophosphamide predisposes to inferior outcome when using cryopreserved stem cell grafts.
Novitzky-Basso, L., et al. (2021) European Journal of Haematology [record in progress]

Cytokine Release Syndrome Following Peripheral Blood Stem Cell Haploidentical HCT with Post-Transplant Cyclophosphamide: CRS post haploidentical HCT with PTCy.
Outoukesh, S., et al. (2021) Transplantation and Cellular Therapy [record in progress]
 

ARTICLE OF THE MONTH Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies. Luznik, L., et al. (2021) Journal of Clinical Oncology: Jco2102293 PICO SUMMARY +++++

17 January 2021 (Monday) - Sysmex Academy Update

The Sysmex Academy sent their update today. It focussed on the Sysmex UK Virtual Symposium 2021 which was held between 23rd and 25th November 2021.

For those of us who missed it, they’ve put the webinars on-line. That’s the way forward, isn’t it?

9 January 2022 (Sunday) - Getting Cross with the BTLP-TACT (again)

Time for a BTLP-TACT exercise. After having my login declined the software suddenly let me in and presented me with two cases 

44046 – a fifty year old woman in the orthopaedic out patient department requiring two units of blood tomorrow.

She grouped as O Rh(D) positive with a positive antibody screen (positive in cells 2 & 3). I requested antibody panels. The enzyme and IAT panels were positive in cells 1, 3, 4, 6 & 7 which corresponded with anti-Jk(a) but did not exclude anti-Cw or anti-E

I selected Jk(a)-negative E-negative units and assumed that Rh Negative units were Cw Negative too

01120 – a forty-seven year old chap in out patients requiring two units of irradiated blood within the hour.

He grouped as A Rh(D) positive with a positive antibody screen (positive in in cell 2). I requested antibody panels. The IAT and enzymes panel were positive in cells 3 & 5 which corresponded with anti-E.

I selected two A Rh(D) positive E-negative units

I got the red light… Apparently I identified antibodies in the first case which weren’t there.. and apparently the software didn’t realise I had selected units of blood for this patient.

I would welcome the opportunity to discuss this with someone at BTLP-TACT… I make a note of each thing I select in the software as I select it, and this isn’t the first time what the report says I selected is at odds with the ongoing notes I make..